Navigation Links
China Interventional Cardiovascular Device Industry Report, 2013-2015
Date:11/20/2013

NEW YORK, Nov. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Interventional Cardiovascular Device Industry Report, 2013-2015

http://www.reportlinker.com/p0370585/China-Interventional-Cardiovascular-Device-Industry-Report-2013-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.

In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%.

Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bioabsorbable everolimus-eluting stent (BVS) has become the focus of attention. Abbott in September 2012 launched the world's first A bioabsorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.

China Interventional Cardiovascular Device Industry Report, 2013-2015 mainly covers the followings: Development, market demand, competition pattern, profit level, etc. of the industry;

Policy environment, impacts from upstream and downstream sectors, etc.;

Market size, supply and demand, product price, etc. of industry segments (including coronary stent, balloon catheter, guide wire, sheath group and auxiliary device), etc.;

Operation, interventional device cardiovascular business, operation in China, etc. of global companies (including Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories, B. Braun);

Operation, interventional cardiovascular device business, etc. of Chinese companies (including MicroPort, Lepu Medical, Lifetech Scientific, JW Medical, Liaoning Bio-medical Technology, OrbusNeich, SCW Medicath, Amtech Biotech and Starway Medical).

1. Overview of Interventional Cardiovascular Device Industry

1.1 Definition

1.2 Product Types and Applications

1.3 Industry Chain

2. Status Quo of China Interventional Cardiovascular Device Industry

2.1 Overview 2.2 Market Demand 2.3 Import and Export2.4 Competition Pattern2.5 Profit2.6 Entry Barriers2.6.1 Technology 2.6.2 Talent 2.6.3 Patent 2.6.4 Policy 2.6.5 Market Access

3. Development Environment for China Interventional Cardiovascular Device Industry

3.1 Policy Environment

3.1.1 Regulatory Policy

3.1.2 Industry Policy

3.2 Upstream and Downstream Sectors

3.2.1 Upstream

3.2.2 Downstream

4. Market Segments

4.1 Coronary Stent4.1.1 Market Profile4.1.2 Drug-Eluting Stent4.1.3 Bare Metal Stent4.1.4 Bioabsorbable Stent4.2 Balloon Catheter4.2.1 Market Profile4.2.2 Supply and Demand4.3 Catheter4.3.1 Market Profile4.3.2 Sales4.4 Guide Wire4.4.1 Market Profile4.4.2 Sales4.5 Sheath Group and Auxiliary Devices4.5.1 Market Profile4.5.2 Sales

5. Foreign Companies

5.1 Johnson & Johnson

5.1.1 Profile

5.1.2 Operation

5.1.3 Interventional Cardiovascular Device Business

5.1.4 Operation in China

5.2 Medtronic

5.2.1 Profile

5.2.2 Operation

5.2.3 Revenue Structure

5.2.4 Operation in China

5.3 Boston Scientific

5.3.1 Profile

5.3.2 Operation

5.3.3 Operation in China

5.4 Abbott Laboratories

5.4.1 Profile

5.4.2 Operation

5.4.3 Operation in China

5.5 B. Braun

5.5.1 Profile

5.5.2 Operation

5.5.3 Operation in China

6. Chinese Companies

6.1 MicroPort6.1.1 Profile6.1.2 Operation6.1.3 Revenue Structure6.1.4 Gross Margin6.1.5 R&D and Investment6.1.6 Interventional Cardiovascular Device Business6.1.7 Forecast and Outlook6.2 Lepu Medical6.2.1 Profile6.2.2 Operation6.2.3 Revenue Structure6.2.4 Gross Margin6.2.5 R&D and Investment6.2.6 Interventional Cardiovascular Device Business6.2.7 Forecast and Outlook6.3 Lifetech Scientific6.3.1 Profile6.3.2 Operation6.3.3 Revenue Structure6.3.4 Gross Margin6.3.5 R&D and Investment6.3.6 Interventional Cardiovascular Device Business6.4 JW Medical6.4.1 Profile6.4.2 Operation6.4.3 Development6.5 Liaoning Bio-medical6.5.1 Profile6.5.2 Operation6.5.3 Development6.6 OrbusNeich6.6.1 Profile6.6.2 Operation6.6.3 Development6.7 Sinomed6.7.1 Profile6.7.2 Operation6.7.3 Development6.8 SCW Medicath6.8.1 Profile6.8.2 Operation6.9 Amtech Biotech6.9.1 Profile6.9.2 Operation 6.10 Starway Medical

Companies Mentioned

Johnson & JohnsonMedtronicBoston ScientificAbbott LaboratoriesB. BraunMicroPortLepu MedicalLifetech ScientificJW MedicalLiaoning Bio-medicalOrbusNeichSinomedSCW MedicathAmtech BiotechStarway MedicalTo order this report: China Interventional Cardiovascular Device Industry Report, 2013-2015 http://www.reportlinker.com/p0370585/China-Interventional-Cardiovascular-Device-Industry-Report-2013-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. CentraState and Freehold Radiology Group train physicians from China
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
6. China Biologic Products Reports Higher Results for the First Quarter 2012
7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
9. China Botanic Attends 67th PHARMCHINA Fair
10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
11. China Botanic Attends the 111th China Import and Export Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):